338 related articles for article (PubMed ID: 20488413)
21. Subacute left main coronary stent thrombosis secondary to a large calcium spicule that produced stent malapposition: OCT and IVUS findings.
Carrizo S; Sanchez-Recalde A; Garcia-Blas S; Moreno R
EuroIntervention; 2015 Nov; 11(7):781. PubMed ID: 25366651
[No Abstract] [Full Text] [Related]
22. Instant Stent-Accentuated 3-Dimensional Optical Coherence Tomography of Struts Pulled Up by Pulling Stuck Wire and Folded by Kissing Balloon Dilation.
Nakao F
JACC Cardiovasc Interv; 2015 Jul; 8(8):e125-e126. PubMed ID: 26117467
[No Abstract] [Full Text] [Related]
23. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study.
Bruining N; de Winter S; Roelandt JR; Regar E; Heller I; van Domburg RT; Hamers R; Onuma Y; Dudek D; Webster MW; Thuesen L; Ormiston JA; Cheong WF; Miquel-Hebert K; Veldhof S; Serruys PW
JACC Cardiovasc Interv; 2010 Apr; 3(4):449-56. PubMed ID: 20398874
[TBL] [Abstract][Full Text] [Related]
24. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent.
Jabara R; Pendyala L; Geva S; Chen J; Chronos N; Robinson K
EuroIntervention; 2009 Dec; 5 Suppl F():F58-64. PubMed ID: 22100678
[TBL] [Abstract][Full Text] [Related]
25. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
[TBL] [Abstract][Full Text] [Related]
26. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
27. Optimal stent expansion and complete neointimal coverage: does this association make sense?
Mintz GS; Choi SY
JACC Cardiovasc Interv; 2009 Oct; 2(10):995-6. PubMed ID: 19850261
[No Abstract] [Full Text] [Related]
28. Kounis syndrome manifesting as coronary aneurysm and very late coronary stent thrombosis.
Hoshi T; Sato A; Akiyama D; Kawabe M; Hiraya D; Aonuma K
JACC Cardiovasc Interv; 2014 Nov; 7(11):e173-6. PubMed ID: 25459048
[No Abstract] [Full Text] [Related]
29. Symptomatic abnormal vessel wall reaction after implantation of the first generation sirolimus-eluting stent: a case series.
Mostafa AE; Richardt G; Abdel-Wahab M
Cardiovasc Revasc Med; 2012; 13(3):196-200. PubMed ID: 22652316
[TBL] [Abstract][Full Text] [Related]
30. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
Costa JR; Abizaid A; Costa R; Feres F; Tanajura LF; Abizaid A; Mattos LA; Staico R; Siqueira D; Sousa AG; Bonan R; Sousa JE
JACC Cardiovasc Interv; 2008 Oct; 1(5):545-51. PubMed ID: 19463357
[TBL] [Abstract][Full Text] [Related]
31. Serial assessment of bioresorbable-polymer sirolimus-eluting stent by coronary angioscopy and optical coherence tomography.
Nakamura S; Kimura S; Nakagama S; Hayashi Y; Yamamoto T; Utsugi Y; Doi J; Mizusawa M; Araki M; Sudo Y; Hishikari K; Hikita H; Takahashi A; Isobe M
Coron Artery Dis; 2017 Sep; 28(6):530-531. PubMed ID: 28402989
[No Abstract] [Full Text] [Related]
32. Serial angiographic and intravascular ultrasound evaluation to interrogate the presence of late "catch-up" phenomenon after Cypher® sirolimus-eluting stent implantation.
Chamié D; Abizaid A; Costa JR; Feres F; Almiro da Silva JF; Mattos LA; Staico R; Costa RA; Abizaid A; Tanajura LF; Sousa AG; Sousa JE
Int J Cardiovasc Imaging; 2011 Jul; 27(6):867-74. PubMed ID: 21082255
[TBL] [Abstract][Full Text] [Related]
33. Sparrow self-expanding sirolimus-eluting stent: do we need a self-expanding coronary stent?
Belardi JA; Albertal M
Catheter Cardiovasc Interv; 2014 Jan; 83(1):25-6. PubMed ID: 24347116
[No Abstract] [Full Text] [Related]
34. Drug-eluting stent fracture: incidence, contributing factors, and clinical implications.
Canan T; Lee MS
Catheter Cardiovasc Interv; 2010 Feb; 75(2):237-45. PubMed ID: 20025045
[TBL] [Abstract][Full Text] [Related]
35. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
[TBL] [Abstract][Full Text] [Related]
36. A case of true left main bifurcation treated with bioresorbable everolimus-eluting stent v-stenting.
Sato K; Latib A; Panoulas VF; Naganuma T; Miyazaki T; Colombo A
JACC Cardiovasc Interv; 2014 Aug; 7(8):e103-4. PubMed ID: 25086841
[No Abstract] [Full Text] [Related]
37. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
[TBL] [Abstract][Full Text] [Related]
38. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial.
Claessen BE; Beijk MA; Legrand V; Ruzyllo W; Manari A; Varenne O; Suttorp MJ; Tijssen JG; Miquel-Hebert K; Veldhof S; Henriques JP; Serruys PW; Piek JJ
Circ Cardiovasc Interv; 2009 Aug; 2(4):339-47. PubMed ID: 20031737
[TBL] [Abstract][Full Text] [Related]
39. Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system: intravascular ultrasound results of the AXXESS PLUS trial.
Miyazawa A; Ako J; Hassan A; Hasegawa T; Abizaid A; Verheye S; McClean D; Neumann FJ; Grube E; Honda Y; Fitzgerald PJ
Catheter Cardiovasc Interv; 2007 Dec; 70(7):952-7. PubMed ID: 18044777
[TBL] [Abstract][Full Text] [Related]
40. The "mini-crush" technique for managing bifurcation lesions.
Kornowski R
Catheter Cardiovasc Interv; 2009 Jul; 74(1):85-7. PubMed ID: 19530202
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
